Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote & News

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 238 8090

Website: eledon.com

Address:

19800 MacArthur Boulevard, Suite 250, Irvine, United States

Veraton Aug. 19 at 11:55 AM

$ELDN Greasing the wheels..

0 · Reply

Ontherag Aug. 19 at 3:07 AM

$ELDN https://www.deseret.com/politics/2026/08/18/mike-lee-push-for-cure-type-one-diabetes/

0 · Reply

cwork Aug. 18 at 8:45 PM

$ELDN Almost there!!! https://youtube.com/shorts/tKpehapLzIU?is=ZV72NzNyXMmIAXZ9

2 · Reply

cwork Aug. 18 at 7:23 PM

$ELDN Agreed 💯 it’s just about time something great is cookin’

0 · Reply

Veraton Aug. 18 at 7:01 PM

$ELDN holdddddd Look at the intraday chart today..... Wear re about to break hard with the next pr.... Massive 🐂

0 · Reply

garrettreid Aug. 18 at 1:41 AM

$ELDN Trial results thus far for Tegoprubart are beyond impressive. However, the stock hasn't moved - most likely because of the cash sitch. One stockholder unfriendly move would be to raise funds at this price or lower and dilute the current shareholder base. Seems pretty obvious that the next logical move would be a licensing deal/partnership with BP. Can anyone tell me whether the CEO has expressed an openness to this possibility in the past?

0 · Reply

Veraton Aug. 17 at 3:15 PM

$ELDN Incentives that matter Gros also has a separate performance bonus tied to Eledon’s market value, with a payout that rises from 6 million dollars at 600 million dollars of market value to 15 million dollars at 1.5 billion dollars, payable in cash, stock, or both. That structure aligns Gros with valuation expansion, not a cheap sale. Perrin and Gros also have change-of-control protections, which is normal for biotech executives and does not itself prove a deal is underway. Capital structure context Eledon shareholders approved increasing authorized common stock from 300 million to 450 million shares in June 2026, giving the company more room to issue equity if needed. The company also reported 88.8 million dollars in cash and investments and a continuing operating-loss profile in its August 2026 10-Q disclosure. That makes stock-settlement flexibility relevant, but it does not by itself imply a takeover or insider accumulation.

2 · Reply

Veraton Aug. 17 at 3:03 PM

$ELDN But the broader corporate setup—450M authorized shares + Gros's unusual valuation incentives + change-of-control provisions + FDA Phase III alignment + 12/12 insulin independence + Gros's Sanofi/M&A background—continues to make strategic transactions worth watching. The next thing I would watch very closely is any new Gros/Perrin Form 4 and exactly what transaction code appears on it. An award (A) is very different from an open-market purchase (P), and either would be different again from equity treatment associated with a transaction.

0 · Reply

Veraton Aug. 14 at 9:13 PM

$ELDN next week phase 3 starting point???

0 · Reply

LifesGood Aug. 14 at 4:53 PM

$ELDN Note: Despite short-term price pressure from financial burn and capital needs, clinical updates for tegoprubart (e.g., strong Phase 2 BESTOW data and Type 1 diabetes islet cell study outcomes) remain structurally positive.

1 · Reply

Eledon Pharmaceuticals reports Q2 EPS (27c), consensus (15c)

Aug 13, 2026, 4:05 PM EDT - 5 days ago

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 13, 2026, 4:00 PM EDT - 5 days ago

Eledon Pharmaceuticals Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 5 days ago

Eledon Pharmaceuticals Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Eledon Pharmaceuticals Slides: Corporate presentation

2026-07-21T10:40:49.000Z - 4 weeks ago

Eledon Pharmaceuticals initiated with a Buy at Rodman & Renshaw

2026-06-25T11:05:47.000Z - 7 weeks ago

Natera, Eledon announce strategic partnership

NTRA

Jun 25, 2026, 7:00 AM EDT - 7 weeks ago

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

NTRA

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Transcript: Study result

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Press release: Study result

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Slides: Study result

2026-06-22T11:41:52.000Z - 2 months ago

Eledon Pharmaceuticals announces new long-term data from BESTOW program

Jun 22, 2026, 7:00 AM EDT - 2 months ago

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

2026-06-08T11:17:05.000Z - 2 months ago

Eledon Pharmaceuticals announces updated results from tegoprubart trial

Jun 8, 2026, 7:00 AM EDT - 2 months ago

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Jun 4, 2026, 4:31 PM EDT - 2 months ago

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

May 20, 2026, 4:05 PM EDT - 3 months ago

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

2026-05-13T21:28:34.000Z - 3 months ago

Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c)

May 13, 2026, 4:05 PM EDT - 3 months ago

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 4:00 PM EDT - 3 months ago

Eledon Pharmaceuticals Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 3 months ago

Eledon Pharmaceuticals Quarterly report: Q1 2026

2026-05-01T20:15:19.000Z - 3 months ago

Eledon Pharmaceuticals files $500M mixed securities shelf

May 1, 2026, 8:00 AM EDT - 3 months ago

Eledon Pharmaceuticals Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

2026-04-20T11:43:42.000Z - 4 months ago

NewcelX announces release of updated presentation on Type 1 Diabetes program

NCEL

Mar 19, 2026, 5:10 PM EDT - 5 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Mar 19, 2026, 4:00 PM EDT - 5 months ago

Eledon Pharmaceuticals Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 5 months ago

Eledon Pharmaceuticals Earnings release: Q4 2025

2026-03-16T11:30:46.000Z - 5 months ago

Eledon announces updated data from islet transplant trial of tegoprubart

Mar 11, 2026, 1:40 PM EDT - 5 months ago

Eledon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-10T11:16:45.000Z - 5 months ago

Eledon Pharmaceuticals announces U.S. FDA granted ODD to tegoprubart

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

2026-03-09T11:12:39.000Z - 5 months ago

NewcelX announces research agreement with Eledon Pharmaceuticals

NCEL

Mar 9, 2026, 7:00 AM EDT - 5 months ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NCEL

Mar 4, 2026, 4:05 PM EST - 5 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Feb 12, 2026, 10:00 AM EST - 6 months ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 4:10 PM EST - 6 months ago

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-23T12:05:49.000Z - 7 months ago

Eledon Pharmaceuticals presents long-term Phase 1b data for tegoprubart

Jan 23, 2026, 7:00 AM EST - 7 months ago

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Jan 8, 2026, 4:05 PM EST - 7 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Dec 4, 2025, 8:50 AM EST - 9 months ago

Eledon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 9 months ago

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

2025-11-18T21:15:53.000Z - 9 months ago

Eledon Pharmaceuticals reports preliminary tegoprubart trial results

Nov 18, 2025, 4:05 PM EST - 9 months ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

2025-11-18T11:35:08.000Z - 9 months ago

Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

2025-11-14T22:05:10.000Z - 9 months ago

Eledon Pharmaceuticals reports Q3 EPS (21c), consensus (25c)

Nov 14, 2025, 5:00 PM EST - 9 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 14, 2025, 4:00 PM EST - 9 months ago

Eledon Pharmaceuticals Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 9 months ago

Eledon Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 10:30 AM EST - 9 months ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-12T13:00:22.000Z - 9 months ago

Eledon prices 15.15M shares at $1.65 in underwritten public offering

Nov 12, 2025, 7:56 AM EST - 10 months ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 11, 2025, 5:26 PM EST - 10 months ago

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 7, 2025, 8:00 AM EST - 10 months ago

Eledon Pharmaceuticals Transcript: Study Result

Nov 7, 2025, 8:00 AM EST - 10 months ago

Eledon Pharmaceuticals Press release: Study Result

Nov 7, 2025, 8:00 AM EST - 10 months ago

Eledon Pharmaceuticals Slides: Study Result

Nov 6, 2025, 6:30 PM EST - 10 months ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Nov 5, 2025, 7:00 AM EST - 10 months ago

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Oct 17, 2025, 7:00 AM EDT - 10 months ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Sep 24, 2025, 4:05 PM EDT - 11 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Sep 5, 2025, 9:10 AM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 14, 2025, 4:20 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: Study Update

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Eledon Pharmaceuticals Press release: Study Update

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Eledon Pharmaceuticals Slides: Study Update

Aug 6, 2025, 4:01 PM EDT - 1 year ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Jul 30, 2025, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 1 year ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: R&D Day 2025

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Slides: FY 2025

Jun 25, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

May 14, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 14, 2025, 12:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Slides: Corporate Presentation

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q4 2024

Mar 11, 2025, 2:20 PM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Feb 5, 2025, 1:00 PM EST - 1 year ago

Eledon Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 7:00 AM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 13, 2024, 1:30 PM EST - 1 year ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 12, 2024, 4:00 PM EST - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Eledon Pharmaceuticals Earnings release: Q3 2024

Oct 29, 2024, 7:46 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 20, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Registration statement: Registration Filing

Sep 11, 2024, 4:05 PM EDT - 2 years ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 2 years ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Aug 14, 2024, 3:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 3:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q2 2024

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 2 years ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

May 30, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

May 24, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Registration statement: Registration Filing

May 9, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 7:30 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 2 years ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Annual report: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q4 2023

Mar 25, 2024, 4:56 PM EDT - 2 years ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 13, 2024, 7:01 PM EST - 2 years ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Veraton Aug. 19 at 11:55 AM

$ELDN Greasing the wheels..

0 · Reply

Ontherag Aug. 19 at 3:07 AM

$ELDN https://www.deseret.com/politics/2026/08/18/mike-lee-push-for-cure-type-one-diabetes/

0 · Reply

cwork Aug. 18 at 8:45 PM

$ELDN Almost there!!! https://youtube.com/shorts/tKpehapLzIU?is=ZV72NzNyXMmIAXZ9

2 · Reply

cwork Aug. 18 at 7:23 PM

$ELDN Agreed 💯 it’s just about time something great is cookin’

0 · Reply

Veraton Aug. 18 at 7:01 PM

$ELDN holdddddd Look at the intraday chart today..... Wear re about to break hard with the next pr.... Massive 🐂

0 · Reply

garrettreid Aug. 18 at 1:41 AM

0 · Reply

Veraton Aug. 17 at 3:15 PM

2 · Reply

Veraton Aug. 17 at 3:03 PM

0 · Reply

Veraton Aug. 14 at 9:13 PM

$ELDN next week phase 3 starting point???

0 · Reply

LifesGood Aug. 14 at 4:53 PM

1 · Reply

cwork Aug. 14 at 3:13 PM

$ELDN https://youtu.be/aKloDU58jk0?is=za8Zj8MhZf3Qb0ue

1 · Reply

Channelchek Aug. 14 at 2:54 PM

Noble Capital Markets Research Report: Eledon Pharmaceuticals ($ELDN) – 2Q26 Reported With Several Tegoprubart Trial Updates 2Q Financial Results Were Within Expectations. Eledon reported a 2Q26 loss of $31.6 million or $(0.27) per share. The Operating Loss of $22.9 million was close to our estimate of $22.4 million, before a charge of $9.6 million for Changes In The Fair Value of Warrant Liabilities. Read full report here: https://www.channelchek.com/news-channel/eledon-pharmaceuticals-eldn-2q26-reported-with-several-tegoprubart-trial-updates

0 · Reply

LifesGood Aug. 14 at 2:51 AM

$ELDN Key Factor to Watch: Financing & Capital Structure: With $88.8 million in cash as of Q2 2026 (projected runway into Q2 2027), biotech investors often monitor whether a company chooses to secure additional institutional capital/offerings around Phase 3 launches, which can temporarily weigh on share price before positive trial readouts play out.

0 · Reply

JInvestTrade Aug. 14 at 1:36 AM

@LeMatt Look at $ELDN. They currently have the only phase 2 drug that has cured T1. This company has huge potential if they get their drug on the market. It would also disrupt all the CGMs on the market.

1 · Reply

BriOnH Aug. 13 at 9:17 PM

$ELDN Stil no friggen color on possible new dosing strategies and/or ibox weighting to improve failure rates vs tac in ph 3. This and possible subcutaneous administration would be really nice to see ASAFP.

1 · Reply

BriOnH Aug. 13 at 9:09 PM

$ELDN "Support the initiation of an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients with renal dysfunction receiving an islet cell transplant in 2026" I attempted to be in this study, Dr. Piotr had his team call me to begin the process of flying me out to start the work, unfortunately my kidneys, despite it being a study with renal dysfunction, my kidneys were not good enough to qualify, that's neither here or there though, the real point here is there is the _possibility_ that removing type 1 from CKD patients w T1, could potentially increase gfr. IF, and that's a big if, that happens sh!t is going to get even crazier. The cost savings this would amount to over time for HMO's would be astronomical. People tend to think its the pharmaceutical companies that have the power and the global interest to keep charging patients, however, the real power here is with HMO's/insurers/payers, as they are ultimately the ones that pay the bills.

0 · Reply

JFais Aug. 13 at 8:44 PM

$ELDN (NP) Dr @stevenvig mentioned this one quite a few times in Chat and gave us a great overview of the science/prospects Q2 report suggests clinical momentum is starting to accelerate IMO (on my DD list)

0 · Reply

Ontherag Aug. 13 at 8:30 PM

$ELDN 88M in cash, but burning 33M a quarter. Expecting a raise or direct offering very soon.

4 · Reply

Veraton Aug. 13 at 8:19 PM

$ELDN RESULTS ARE OUT... EVERYTHING LOOKING GOOD EVERYTHING ON TRACK!!! EXPECTING SEVERAL RESUMTS BEFORE YEARS END! CASH THROUGH 2Q 2027 Continue to be bullish!

0 · Reply

Penny_stock_Raid_Boss Aug. 13 at 6:34 PM

$ELDN one fifth of the median daily volume

0 · Reply

Veraton Aug. 13 at 1:49 PM

$ELDN Are we having earnings news today??? I just want to listen to some guidance for the rest of the year specially phase 3 pathway FDA APPROVED MASSIVE 🐂

1 · Reply

cwork Aug. 13 at 3:00 AM

$ELDN 2 years of being functionally cured of T1D because of Tego!! https://youtube.com/shorts/6Nrc6Am2Bhk?is=xMGQ2zKzeoJ89ITr

0 · Reply

Market Cap	276.33M
Revenue (ttm)	0.00
Net Income (ttm)	-45.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	612,900
Avg Vol	1,366,564
Day's Range	N/A - N/A
Shares Out	77.19M
Stochastic %K	46%
Beta	0.98
Analysts	Strong Sell
Price Target	$9.50